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A high dose of whey protein hydrolysate fed with milk minerals rich in calcium 52 
(Capolac®) results in enhanced glucagon-like peptide-1 (GLP-1) concentrations in 53 
lean individuals, however the effect of different calcium doses ingested alongside 54 
protein is unknown. The present study assessed the dose response of calcium fed 55 
alongside 25 g whey protein hydrolysate on GLP-1 concentrations in individuals with 56 
overweight/obesity. Eighteen adults (mean ± SD: 8M/10F, 34 ± 18 years, 28.2 ± 2.9 57 
kg∙m-2) completed 4 trials in a randomised, double-blind, crossover design. 58 
Participants consumed test solutions consisting of 25 g whey protein hydrolysate 59 
(CON), supplemented with 3179 mg (LOW), 6363 mg (MED), or 9547 mg (HIGH) 60 
Capolac® on different occasions, separated by at least 48 hours. The calcium content 61 
of test solutions equated to 65, 892, 1719 and 2547 mg, respectively. Arterialised-62 
venous blood was sampled over 180 min to determine plasma concentrations of GLP-63 
1TOTAL, GLP-17-36amide, insulin, glucose, non-esterified fatty acids (NEFA), and serum 64 
concentrations of calcium and albumin. Ad libitum energy intake was measured at 180 65 
min. Time-averaged incremental area under the curve (iAUC) for GLP-1TOTAL (pmol·L-66 
1·min-1) did not differ between CON (23 ± 4), LOW (25 ± 6), MED (24 ± 5), and HIGH 67 
(24 ± 6). Energy intake (kcal) did not differ between CON (940 ± 387), LOW (884 ± 68 
345), MED (920 ± 334), and HIGH (973 ± 390). Co-ingestion of whey protein 69 
hydrolysate with Capolac® does not potentiate GLP-1 release in comparison to whey 70 






Glucagon-like peptide-1 (GLP-1) is a peptide hormone produced by intestinal L-cells 77 
(1). Its release stimulates glucose-dependent insulin secretion (2), delays gastric 78 
emptying (3), and reduces food intake (4). These actions, among others, act to preserve 79 
metabolic health such that GLP-1 agonism has been targeted for obesity and type 2 80 
diabetes (T2D) management (5). Strategies including bariatric surgery, administration 81 
of GLP-1 agonists, and dipeptidyl peptidase-IV inhibitors (DPP4 rapidly inactivates 82 
GLP-1 upon binding) have been effective at increasing/preserving GLP-1 action and 83 
promoting weight loss and greater glycaemic control (5; 6; 7; 8).  However, it is also 84 
important to understand the regulation of endogenous GLP-1 through nutrition, 85 
whereby enhancement of gut hormones through specific targeted nutrition can be 86 
implemented for wide-scale use. 87 
 88 
Nutrition potently regulates enteroendocrine cell action and subsequent peptide 89 
hormone release through nutrient sensing and absorption (9). Recent evidence has 90 
implicated the calcium sensing receptor (CaSR), which is expressed on intestinal L-91 
cells, with facilitating gut hormone release across in vitro (10; 11), ex vivo (12; 13) and in 92 
vivo rodent models (14). CaSR is responsive to extracellular calcium and amino 93 
acids/peptides at physiological fasting and postprandial concentrations (15; 16). 94 
 95 
The administration of calcium and hydrolysed protein to stimulate GLP-1 secretion 96 
was first investigated using an ex vivo rodent model (12). The small intestine was 97 
perfused with a KHB buffer in the presence or absence of 10 mM phenylalanine. 98 
Calcium was then introduced with increasing dose from 0.1 to 10 mM. GLP-1 99 
concentrations were augmented with increasing calcium dose only in the presence of 100 
phenylalanine (12). More recent work in lean humans is consistent with these 101 
observations, whereby plasma GLP-1TOTAL iAUC was 25% greater over 2 h following 102 
acute ingestion of 50 g whey protein with Capolac® compared to the ingestion of 50 g 103 
whey protein alone (17). Furthermore, peak GLP-1 concentrations measured following 104 
the ingestion of whey protein and Capolac® were some of the highest recorded in 105 
humans following nutrient ingestion (91 ± 20 pmol·L-1).  106 
 107 
The previous study selected a large dose of protein as part of a proof of principle 108 
design. However, it remains unclear whether this effect persists in an 109 
overweight/obese population and when feeding a practically relevant dose of protein 110 
more reflective of that ingested during a standard meal i.e 25 g. For instance, total 111 
protein content of breakfast, lunch, and dinner for adults is approximately 15 g, 23 g, 112 
and 35 g, respectively (18). Moreover, the dose of calcium required alongside protein 113 
to effectively stimulate the relevant gut hormone response is yet to be established. 114 
Accordingly, the aim of this study was to assess the dose-response of calcium fed 115 
alongside a practically relevant dose of protein on GLP-1 release in individuals who 116 
are overweight/obese. It was hypothesised that GLP-1 concentrations would rise with 117 
increasing dose of calcium.  118 
 119 
METHODS 120 
Experimental design 121 
Eighteen overweight men and women (Table 1) were recruited to participate in a 122 
double-blinded randomised crossover study with 4 trial arms. Inclusion criteria 123 
included age 18-65 y, BMI 25.0-34.9 kg∙m-2, no history of metabolic disease, and free 124 
from allergies or altercations to calcium or milk proteins. Following written consent, 125 
participants were randomly assigned to a counterbalanced trial sequence by a 126 
researcher who was not involved in data collection. The study protocol was approved 127 
by the University of Bath Research Ethics Approval Committee for Health (REACH 128 
REF: EP 17/18 250). All procedures were carried out in accordance with the 129 
declaration of Helsinki. The study was registered at https://clinicaltrials.gov/ 130 
(NCT03819972).  131 
 132 
Table 1 Participant characteristics  133 
Values are mean ± SD 134 
 135 
Pre-trial standardisation 136 
Participants recorded their habitual diet for 24 h prior to trial 1, then replicated this diet 137 
for 24 h prior to each subsequent trial. They also refrained from caffeine, alcohol and 138 
any vigorous physical activity for 24 h prior to each trial day. Participants were provided 139 
with a standardised meal (Tesco spinach and ricotta cannelloni 440 g; 463 kcal, 56.3 140 
g carbohydrate, 10.1 g sugars, 25.0 g fat, 23.8 g protein) which was consumed no 141 
later than 10:00 pm the evening before a trial day. Women were tested at different 142 
phases of their menstrual cycle as this was considered most representative of real life. 143 
The washout period between trials was between 2-7 days.  144 
 145 
 Total Males Females 
Sample size (n) 18 8 10 
Age (years) 34 ± 18 28 ± 14 38 ± 20 
Body mass (kg) 81.2 ± 12.5 89.0 ± 12.3 74.9 ± 8.8 
Body mass index (BMI; kg·m-2) 28.2 ± 2.9 29.1 ± 3.4 27.4 ± 2.4 
Fasting glucose (mmol·L-1) 5.5 ± 0.5  5.5 ± 0.5 5.5 ± 0.7 
Fasting insulin (pmol·L-1) 41 ± 20 43 ± 20 40 ± 21 
Trial days 146 
Participants arrived at the laboratory between 08:00-10:00 h following a 10-14 h 147 
overnight fast (standardised within participants). Water consumption was permitted ad 148 
libitum, with volume recorded on the first trial, and replicated on the subsequent trials. 149 
Height was measured using a stadiometer (Seca Ltd., Birmingham, UK), with 150 
participants barefoot in the Frankfurt plane. Body mass was measured using digital 151 
scales (Tanita, Amsterdam, The Netherlands) with participants barefoot and wearing 152 
light clothing.  153 
 154 
Arterialised-venous blood samples were obtained by retrograde cannulation of a pre-155 
heated dorsal hand vein or, if unsuccessful, an antecubital arm vein (standardised 156 
within participants). After a baseline blood sample and visual appetite scale, test 157 
solutions were consumed within a 5-min window (trial commenced upon the first 158 
mouthful of the test solution). The time taken to ingest the test solution on trial 1 was 159 
recorded and replicated for each subsequent trial. Following ingestion, palatability and 160 
blinding validation scales were completed. Blood samples were taken at 15, 30, 45, 161 
60, 90, 120, and 180 min post-ingestion. Appetite visual analogue scales (VAS) were 162 
obtained at baseline and every hour throughout the postprandial period. At the end of 163 
this period participants ingested an ad libitum lunch (Tesco Hearty Food Co cheese 164 
and tomato pasta 400 g; nutritional info per 100 g, 118 kcal, 19.9g carbohydrate, 15.9 165 
g sugars, 6.8 g fat, 14.3 g protein) until they were comfortably full and did not want to 166 
consume any more. This was followed by another VAS and palatability scale. Upon 167 
the completion of the final trial participants completed a restrained eating 168 
questionnaire. The protocol is outlined in Figure 1.    169 
 170 
Test solutions 171 
There were 4 test solutions consumed in a randomised, counterbalanced order over 172 
4 trials: 1) whey protein hydrolysate [29.8 g dry powder providing 25 g protein and 15 173 
mg calcium; CON; Lacprodan® DI-3091; (Arla Foods Ingredients, Viby J, Denmark)]; 174 
2) Whey protein hydrolysate plus milk minerals rich in calcium, Capolac® (Arla Foods 175 
Ingredients, Viby J, Denmark) [3179 mg to provide 842 mg calcium; LOW;]; 3) Whey 176 
protein hydrolysate plus Capolac® (6363 mg to provide 1669 mg calcium; MED;); 4) 177 
Whey protein hydrolysate plus Capolac® (9547 mg to provide 2497 mg calcium; 178 
HIGH;). Calcium concentrations for each condition increased linearly up to the 179 
maximal tolerable dose in HIGH. The calcium content in the local tap water was 99.58 180 
mg·L-1 (19) and day to day variation is <15 mg which is unlikely to alter any responses 181 
measured (17). A tap water contribution of 50 mg calcium per 500 ml drink is included 182 
in the composition given in Table 2. Test solutions were prepared by two researchers 183 
not involved with data collection by dissolving both the protein and Capolac® together 184 




Figure 1. Schematic of trial days 
Table 2 Nutritional composition of the test meal for each condition   189 
Ingredient Condition    
 CONa LOWb MEDc HIGHd 
Energy (kJ) 438 444 449 455 
Energy (kcal) 105 106 107 109 
Water (ml) 500 500 500 500 
Sucralose (mg) 80 80 80 80 
Calcium (mg)e 65 892 1719 2547 
Phosphorus (mg) 60 410 760 1110 
Magnesium (mg) 15 37 60 82 
Protein (g) 25 25 25 25 
Carbohydrate (g) 0.6 0.9 1.1 1.4 
Fat (g) < 0.1 < 0.1 < 0.1 < 0.1 
aCON, whey protein hydrolysate; bLOW, whey protein hydrolysate with a low dose of 190 
Capolac®; cMED, whey protein hydrolysate with a medium dose of Capolac®; dHIGH, 191 
whey protein hydrolysate with a high dose of Capolac®; ereported calcium value 192 
includes the estimated tap water content. 193 
 194 
Blood sampling and analysis 195 
A 10-mL blood sample was collected for sampling of arterialised venous blood at each 196 
timepoint. This was dispensed into 1) 5-mL EDTA collection tubes (Sarstedt, 197 
Nümbrecht, Germany); 2) 3-mL untreated blood collection tubes (Sarstedt, 198 
Nümbrecht, Germany); and 3) 2-mL p800 tubes (BD, New Jersey, USA) containing a 199 
cocktail of enzyme inhibitors. Plasma samples (EDTA and p800 tubes) underwent 200 
immediate centrifugation, whereas untreated blood collection tubes were allowed to 201 
clot at room temperature for 15 minutes before being centrifuged to extract blood 202 
serum. All samples were centrifuged at 4000 g for 10 minutes at 4oC and plasma and 203 
serum collected and frozen immediately on dry ice. Samples were stored at -80oC until 204 
further analysis.  205 
 206 
Plasma GLP-1TOTAL, GLP-17-36amide, and insulin were measured using commercially 207 
available enzyme-linked immunosorbent assays (ELISA, GLP-1, Merck Millipore, 208 
Watford, UK; Insulin, Mercodia, Uppsala, Sweden).  The antibodies in the GLP-1TOTAL 209 
assay are specific to both GLP-17-36amide and GLP-19-36amide, and therefore the GLP-210 
1TOTAL assay is indicative of total secretion whereas the GLP-17-36amide assay is 211 
indicative of hormone action (20). All samples for comparison between treatments within 212 
each participant were included on the same plate and the respective intra-plate CVs 213 
for GLP-1TOTAL, GLP-17-36amide and Insulin were 6.1%, 6.1%, and 7.4%, respectively.   214 
Plasma glucose and NEFA and serum calcium and albumin were analysed in singular 215 
using a spectrophotometric analyser (Randox, Daytona, Randox Laboratories Ltd., 216 
Crumlin, UK).  217 
 218 
Subjective appetite ratings 219 
Subjective ratings of appetite were assessed using a previously validated 100-mm 220 
visual analogue scale (VAS) (21). The four questions from this scale: ‘How hungry do 221 
you feel?’, ‘How full do you feel?’, ‘How satisfied do you feel?’, and ‘How much do you 222 
think you can eat?’ can be used and then converted into a composite appetite score. 223 
This score combines hunger, fullness, satisfaction, and prospective consumption 224 
using the following equation (22).  225 
 226 
Appetite score = (hunger + prospective food consumption + (100 - fullness) + (100-227 
satisfaction))/4 228 
 229 
Statistical analysis  230 
The primary outcome was the iAUC for plasma GLP-1TOTAL. Plasma GLP-17-36amide, 231 
insulin, glucose and NEFA, and serum calcium and albumin were secondary 232 
outcomes, alongside VAS and ad libitum energy intake. The sample size calculation 233 
was based on our previous data(17) in which the mean difference for postprandial 234 
plasma GLP-1TOTAL between the co-ingestion of whey protein and Capolac® versus 235 
whey protein alone, was 9.1 ± 6.9 pmol·L-1·120 min-1 (mean ± SD). Using this effect 236 
size (d = 1.32), approximately 18 participants (16 participants for blood data) provides 237 
an 90% probability (85% for blood data) of detecting such an effect with an α-level of 238 
0.05 using a one-way, repeated-measures ANOVA with two tails. Data are presented 239 
as means ± SD in text, and means ± 95% normalised confidence intervals (nCI) in 240 
figures, corrected for between-participant variation, such that the magnitude of the 241 
nCI’s directly infers the contrast between paired means at each time-point rather than 242 
variance of individual values around the mean (23). The iAUC or total AUC (tAUC) was 243 
calculated for all variables (other than ad libitum energy intake) using the Time Series 244 
Response Analyser (24). One-way ANOVAs were employed to assess differences 245 
between non-time dependent variables (i.e. iAUC, ad libitum energy intake), whereas 246 
differences between time-dependent variables were analysed using a 2-way repeated-247 
measures ANOVA (condition-time). ANOVAs are considered robust to violations to 248 
normality assumptions (25). Where data points were missing, mixed effects models 249 
were employed. Where an interaction effect was determined, post-hoc comparisons 250 
were adjusted for multiple comparisons using the stepwise Holm-Bonferroni 251 
correction. Simple linear regression was used to determine whether BMI and HOMA-252 
IR could predict GLP-1 concentrations. A two-tailed p value of ≤ 0.05 was deemed 253 
statistically significant. Results were analysed using Microsoft Excel version 16.0 and 254 
GraphPad Prism version 8.4.3.   255 
 256 
RESULTS 257 
Plasma GLP-1  258 
For postprandial change in plasma GLP-1TOTAL and GLP-17-36amide concentrations 259 
there was no main effect of trial (p = 0.24 and p = 0.34, respectively) or trial x time 260 
interaction (Fig 2A-B; p = 0.22 and p = 0.43, respectively). There was also no 261 
significant differences in plasma GLP-1TOTAL time-averaged iAUC (Fig 2C; p = 0.57, 262 
CON (24 ± 9 pmol·L-1·min-1); LOW (24 ± 8 pmol·L-1·min-1); MED (23 ± 8 pmol·L-1·min-263 
1); HIGH (24 ± 7 pmol·L-1·min-1)) and GLP-17-36amide time-averaged iAUC between 264 
conditions (Fig 2D; p = 0.59, CON (1.7 ± 1.2 pmol·L-1·min-1): LOW (1.6 ± 0.9 pmol·L-265 
1·min-1); MED (1.4 ± 1.1 pmol·L-1·min-1); HIGH (1.3 ± 1.0 pmol·L-1·min-1)). GLP-1TOTAL 266 
time-averaged iAUC did not differ between males and females (p = 0.90), however, 267 
GLP-17-36amide time-averaged iAUC was greater for females compared to males (p = 268 
0.02). There was, however, no difference between conditions for males or females, 269 
respectively, for both GLP-1TOTAL time-averaged iAUC (p = 0.53, p = 0.74) and GLP-270 
17-36amide time-averaged iAUC (p = 0.32, p = 0.39). Peak plasma GLP-1TOTAL 271 
concentrations were 64 ± 19 pmol·L-1, 62 ± 17 pmol·L-1, 61 ± 14 pmol·L-1 , and 62 ± 272 
17 pmol·L-1  for CON, LOW, MED and HIGH conditions, respectively, and were not 273 
statistically different (p = 0.75). Similarly, peak plasma GLP-17-36amide concentrations 274 
did not differ between conditions (p = 0.30). There was also no main effect of trial (p > 275 
0.99) or trial x time interaction for GLP-17-36amide:GLP-1TOTAL ratio (p = 0.99). Change 276 
in postprandial GLP-1 iAUC (HIGH minus CON) was not significantly correlated with 277 
either BMI (Fig 3A, r2 = 0.05, p = 0.42) or Homeostatic Model Assessment of Insulin 278 
Resistance (HOMA-IR; Fig 3B, r2 = 0.08, p = 0.30), nor was peak GLP-1TOTAL 279 
significantly correlated with BMI (Fig 3A, r2 = 0.09, p = 0.27) or HOMA-IR (Fig 3A, r2 = 280 
0.02, p = 0.63). 281 
Figure 2. Plasma GLP-1TOTAL (A) and GLP-17-36amide concentrations (B) and time-
averaged iAUC values for plasma GLP-1TOTAL (C) and GLP-17-36amide (D) following 
ingestion of protein hydrolysate (CON), and protein hydrolysate and a low (LOW), 
medium (MED), and high (HIGH) dose of Capolac®. Solid and dashed lines represent 
individual data for males and females, respectively. Data are means  95% nCI, n = 
16, CON = 15, LOW = 15, MED = 16, HIGH = 16. GLP-1 glucagon-like peptide-1. 
Significance was set at p ≤ 0.05.     
 282 
 283 
Plasma insulin, glucose and NEFA 284 
There were no differences in plasma insulin (p = 0.51), glucose (p = 0.94), or NEFA 285 
(p = 0.44) between conditions at baseline.  Following the ingestion of test drinks, there 286 
was no effect of trial or trial x time interaction for plasma insulin (Figure 4A, p = 0.92 287 
and p = 0.67, respectively), plasma glucose (Figure 4B, p = 0.92 and p = 0.41, 288 
respectively), or plasma NEFA (Figure 4C, p = 0.35 and p = 0.11, respectively). The 289 
subsequent time-averaged iAUCs for plasma insulin (p = 0.83, CON (85 ± 61 pmol·L-290 
1·min-1); LOW (82 ± 96 pmol·L-1·min-1); MED (86 ± 90 pmol·L-1·min-1); HIGH (83 ± 84 291 
Figure 3. Simple linear regression for plasma GLP-1TOTAL iAUC (change from HIGH 
minus CON) and BMI (A) and HOMA-IR (B) and for peak plasma GLP-1 and BMI (C) 
and HOMA-IR (D). Filled circles and open circles represent male and females, 
respectively. n = 16. GLP-1 glucagon-like peptide-1. Significance was set at p ≤ 0.05.     
pmol·L-1·min-1)) and plasma glucose (p = 0.79, CON (0.10 ± 0.25 mmol·L-1·min-1); 292 
LOW (0.08 ± 0.22 mmol·L-1·min-1); MED (0.06 + 0.13 mmol·L-1·min-1); HIGH (0.05 ± 293 
0.08 mmol·L-1·min-1)), and the time-averaged tAUC for plasma NEFA (p = 0.57, CON 294 
(0.24 ± 0.10 pmol·L-1·min-1); LOW (0.24 ± 0.12 pmol·L-1·min-1); MED (0.24 ± 0.00 295 

















Figure 4. Plasma insulin (A), glucose (B) and NEFA concentrations (C) following 
ingestion of protein hydrolysate (CON), and protein hydrolysate and a low (LOW), 
medium (MED), and high (HIGH) dose of Capolac®. Data are means  95% nCI, n 
= 16. NEFA Non-esterified fatty acids. Significance was set at p ≤ 0.05.     
 313 
Serum calcium and albumin 314 
There was no effect of trial or trial x time interaction for either serum calcium (Fig 5A, 315 
p = 0.70 and p = 0.45, respectively) or albumin (Fig 5B, p = 0.92 and p = 0.41, 316 
respectively). There was also no differences observed in the time-averaged iAUC for 317 
serum calcium (p = 0.37, CON (0.10 ± 0.14 mmol·L-1·min-1); LOW (0.10 ± 0.14 mmol·L-318 
1·min-1); MED (0.05 ± 0.10 mmol·L-1·min-1); HIGH (0.16 ± 0.26 mmol·L-1·min-1)) or 319 
serum albumin (p = 0.31, CON (1.8 ± 2.6 g·L-1·min-1); LOW (1.7 ± 2.8 g·L-1·min-1); 320 





Ad libitum lunch and VAS 326 
There was no difference in ad libitum lunch energy intake between conditions (Fig 6A; 327 
p = 0.35, CON (940 ± 387 kcal); LOW (884 ± 345 kcal); MED (920 ± 334 kcal); HIGH 328 
(973 ± 390 kcal)). Equally, there were no effects for trial or trial by time interaction for 329 
Figure 5. Serum Calcium (A) and albumin concentrations (B) following ingestion of 
protein hydrolysate (CON), and protein hydrolysate and a low (LOW), medium 
(MED), and high (HIGH) dose of Capolac®. Data are means  95% nCI, n = 16. 
Significance was set at p ≤ 0.05.     
ratings of perceived fullness, satisfaction, hunger, prospective consumption or overall 330 
appetite score (Fig 6C, all p > 0.05). There was a significant difference in postprandial 331 
appetite iAUC between conditions (Fig 6B, p = 0.04), although differences did not 332 

















Figure 6. Ad libitum energy intake (A), time-averaged postprandial  tAUC values 
for appetite (B) and overall appetite score (C) following ingestion of protein 
hydrolysate (CON), and protein hydrolysate and a low (LOW), medium (MED), and 
high (HIGH) dose of Capolac®. Solid and dashed lines represent individual data 
for males and females, respectively. PL, post lunch. Data are means  95% nCI, 
n = 18, Significance was set at p ≤ 0.05.  
 350 
Standardisation and blinding  351 
The test drinks were well tolerated by all participants and were correctly identified on 352 
only 26% of occasions, with a third of participants unable to identify a single drink 353 
correctly. There was no difference in the time taken to ingest the test drink between 354 
conditions (p = 0.07; 260 ± 80 s, 257 ± 91 s, 264 ± 83 s and 288 ± 72 s, for CON, 355 
LOW, MED and HIGH, respectively). Data were checked for order effects and the only 356 
parameters that exhibited any evidence of systematic variance over trial were plasma 357 
glucose and serum albumin, for which there was a main trial effect of trial sequence 358 
(both p = 0.03), but without any sequence x trial interaction. 359 
 360 
DISCUSSION 361 
The present study reveals that, contrary to our hypothesis based on previous data, the 362 
postprandial plasma GLP-1 response is not accentuated by the addition of Capolac® 363 
to ingested whey protein hydrolysate (25 g), regardless of the calcium dose across a 364 
range of 65-2547 mg. Neither plasma concentrations of insulin, glucose and NEFA nor 365 
serum concentrations of calcium and albumin differed meaningfully between 366 
conditions. There is also no effect of calcium dose on ad libitum energy intake from 367 
the lunch meal or overall subjective ratings of appetite. 368 
 369 
The absence of any difference in plasma GLP-1TOTAL or GLP-17-36amide concentrations 370 
between conditions in the present study is interesting considering these findings 371 
contradict previous work where supplementing meals with calcium enhances GLP-1 372 
concentrations in comparison to meals without supplementation (26; 27; 28). Furthermore, 373 
the combination of calcium and protein/amino acids has been shown to potently 374 
stimulate GLP-1 release through co-ingestion, in vivo (17), and administration, ex vivo 375 
(12). The contrasting results of the present study compared to previous research may 376 
be explained by either the protein dose of the test drinks, or the population sampled in 377 
the study.  378 
 379 
In our previous work, a large dose of whey protein hydrolysate was selected in a proof 380 
of concept study design (Chen et al., 2019). Interestingly, plasma GLP-1TOTAL time-381 
averaged iAUC in the HIGH condition of the present study (25 g whey protein 382 
hydrolysate) was almost half the concentration (24 ± 6 pmol·L-1· 180 min-1) of that 383 
recorded following the consumption of 50 g whey protein hydrolysate (double the dose 384 
of the present study) and ~ 1000 mg Capolac® (45 ± 6 pmol·L-1· 120 min-1) (17). Equally, 385 
the protein-calcium synergy reported ex vivo, used isolated loops of rat small intestine 386 
where phenylalanine was perfused at a very large dose equating to 10 mmol•L-1 (12). 387 
Following the ingestion of a protein rich meal (50 g bovine serum albumin) in humans, 388 
ileal concentrations of phenylalanine as free and peptide amino acids reach (mean ± 389 
SEM) 0.36 ± 0.08 and 1.65 ± 0.33 mmol·L-1, respectively (29), which means enhanced 390 
stimulation of GLP-1, mediated by protein and calcium, has only been reported at high 391 
protein concentrations. Within the intestinal epithelium, L-cells capable of releasing 392 
GLP-1 increase in density along the length of the intestinal epithelium, with the 393 
greatest number located in the colon (9). This may suggest that a larger protein dose 394 
is required to reach more distal sections of the intestine for calcium to influence GLP-395 
1 release. Additionally, while at low doses, calcium is primarily absorbed in the 396 
duodenum and jejunum via saturable transcellular processes, at normal to high doses, 397 
the non-saturable paracellular diffusive pathway occurs throughout the intestine but 398 
dominates more distally, in the jejunum and ileum (30; 31; 32). Considering the ingestion 399 
of large calcium doses in the present study, the limiting factor for protein and calcium 400 
mediated GLP-1 release could be the amount of protein fed. Protein and calcium 401 
induced GLP-1 release is thought to act via the synergistic stimulation of the Calcium 402 
sensing receptor (CaSR) (12; 16). The CaSR is able to sense amino acids in the 403 
presence of extracellular calcium concentrations of 0.5 – 10 mM (15). Furthermore, 404 
while being directly activated by calcium, occupancy of the L-amino acid binding site 405 
enhances the sensitivity of CaSR to calcium (16; 33), meaning that protein and calcium 406 
may work through allosteric activation of the receptor to further enhance GLP-1 407 
concentrations. CaSR is also thought to be expressed on the basolateral membrane 408 
meaning protein absorption is paramount for GLP-1 release (13). Therefore, insufficient 409 
protein absorption and binding may be limiting to CaSR-mediated GLP-1 release.  410 
 411 
Another potential explanation as to why the addition of calcium did not exert the 412 
expected effect on GLP-1 could relate to the population studied. In the present study, 413 
individuals who were classified as overweight/obese were recruited to determine 414 
whether protein and calcium mediated GLP-1 release, seen in lean participants(17), 415 
was preserved. GLP-1 release in adults with overweight and obesity has been shown 416 
to be impaired in comparison to lean controls (34; 35), which could suggest a disruption 417 
in the signalling pathways resulting in GLP-1 release, including those involved with 418 
CaSR mediated GLP-1 release. However, these findings are inconsistent and reduced 419 
-cell function, rather than a reduction in GLP-1 release, is often cited as a driver of 420 
the impaired incretin effect often observed in obese and diabetic populations (36; 37). 421 
Moreover, in the present study there was no correlation between BMI or HOMA-IR 422 
and GLP-1TOTAL iAUC, or between BMI or HOMA-IR and peak plasma GLP-1TOTAL, 423 
suggesting that body composition and insulin sensitivity were not associated with GLP-424 
1 concentrations, at least in the present study. Importantly, if population differences in 425 
GLP-1 release do exist, and are mediated by factors such as BMI and insulin 426 
sensitivity, this impairment may not be linear with increasing BMI/insulin resistance but 427 
instead occur at distinct thresholds, that could not be captured in the population 428 
sampled in this study. 429 
 430 
Despite no differences in postprandial plasma GLP-1 concentrations between 431 
conditions the average peak GLP-1TOTAL concentration for the HIGH condition (62 ± 432 
17 pmol·L-1) was greater than those reported following the ingestion of 30 g whey 433 
protein isolate (120 kcal) in healthy older men (n = 8) and women (n = 8) (~ 40 pmol·L-434 
1) (38) and 45 g whey protein isolate (311 kcal) in nine obese young women (~ 50 435 
pmol·L-1) (39). Whilst inter-study comparisons should be made with caution the higher 436 
plasma peak GLP-1 concentrations in the present study are unlikely due to the assay 437 
employed as it’s been shown to have good precision and specificity for GLP-1TOTAL 438 
(40). Furthermore, fasting concentrations of GLP-1TOTAL (26 ± 17 pmol·L-1) are similar 439 
to those reported in the aforementioned studies. Greater plasma GLP-1 440 
concentrations observed in the present study could be at least partly due to the form 441 
of whey protein ingested, whereby hydrolysed whey protein is likely to increase free 442 
amino acid exposure to the intestine (41).  443 
 444 
Serum calcium was not different between conditions in the present study despite such 445 
large differences in dose consumed. Calcium balance results mainly from the net 446 
effects of intestinal absorption and renal, intestinal and parathyroid gland excretion 447 
into the dominant calcium pool, bone (31; 42). PTH and Vitamin D are two key calcium-448 
regulating hormones, which integrate to increase bone resorption or intestinal 449 
absorption at high and low calcium concentrations, respectively (42; 43). These 450 
mechanisms maintain calcium concentrations within a narrow physiological range of 451 
~2.5mM (10%) (31; 42).  The content of other minerals such as phosphorous and 452 
magnesium in each test solution differed marginally (table 2), however, this is not likely 453 
to influence gut hormone concentrations. Previously, GLP-1TOTAL iAUC was not 454 
different following ingestion of calcium citrate (< 1 mg phosphorous, < 1 mg 455 
magnesium) versus milk minerals rich in calcium (551 mg phosphorous, 26 mg 456 
magnesium) (17). 457 
  458 
In conclusion, the co-ingestion of a practically relevant dose of whey protein with a 459 
high dose of Capolac® did not potentiate GLP-1 release in comparison to whey protein 460 
hydrolysate alone, in people with overweight/obesity. Furthermore, ad libitum energy 461 
intake and subjective ratings of appetite did not differ between conditions. Future 462 
research should investigate whether there is a protein dose threshold for protein- and 463 
calcium-mediated GLP-1 release and whether this effect is specific to metabolically 464 
healthy populations or also present in clinical populations with metabolic diseases. 465 
 466 
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